We used curated survival data from the TCGA Clinical Data Resource to perform tumor-specific survival analyses stratified by BAP1 activity class and noted improved progression-free survival outcomes for wildtype-like UVM and KIRC tumors (Supplementary Figure S6) (49). This evidence concerns the gene BAP1 and neoplasm.